These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 37485850)

  • 41. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
    Taube JM; Klein A; Brahmer JR; Xu H; Pan X; Kim JH; Chen L; Pardoll DM; Topalian SL; Anders RA
    Clin Cancer Res; 2014 Oct; 20(19):5064-74. PubMed ID: 24714771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1.
    Ibrahim AA; Fujimura T; Uno T; Terada T; Hirano KI; Hosokawa H; Ohta A; Miyata T; Ando K; Yahata T
    Front Immunol; 2024; 15():1365894. PubMed ID: 38779680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
    Mudassar F; Shen H; Cook KM; Hau E
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
    Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
    Front Immunol; 2021; 12():619209. PubMed ID: 33790893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
    Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
    Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models.
    Shi X; Shu L; Wang M; Yao J; Yao Q; Bian S; Chen X; Wan J; Zhang F; Zheng S; Wang H
    Adv Sci (Weinh); 2023 May; 10(15):e2204890. PubMed ID: 37017572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review.
    Zhou Z; Wang H; Li J; Jiang X; Li Z; Shen J
    Int J Biol Macromol; 2024 Jan; 254(Pt 2):127911. PubMed ID: 37939766
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles.
    Zhao M; Yang X; Fu H; Chen C; Zhang Y; Wu Z; Duan Y; Sun Y
    ACS Appl Mater Interfaces; 2021 Jul; 13(28):32763-32779. PubMed ID: 34235912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systems pharmacology: a combination strategy for improving efficacy of PD-1/PD-L1 blockade.
    Zheng C; Xiao Y; Chen C; Zhu J; Yang R; Yan J; Huang R; Xiao W; Wang Y; Huang C
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33876189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
    Zhang R; Wan Y; Lv H; Li F; Lee CS
    J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.
    Fan J; Shen X; Wang Y; Zhou HL; Liu G; Li YL; Xu ZX
    Biomed Pharmacother; 2020 Oct; 130():110621. PubMed ID: 34321165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
    Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
    Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy.
    Zhang Q; Yang C; Gao X; Dong J; Zhong C
    Phytother Res; 2024 Feb; 38(2):776-796. PubMed ID: 38050789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.
    Kaneko K; Acharya CR; Nagata H; Yang X; Hartman ZC; Hobeika A; Hughes PF; Haystead TAJ; Morse MA; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Augmented Antitumor Effect of Unripe
    Lee EJ; Yang JH; Choi JG; Chung HS
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
    Du B; Wen X; Wang Y; Lin M; Lai J
    Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.